<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=Windows-1252">
</head>
<body style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space;">
<br>
<div>
<blockquote type="cite">
<div lang="EN-US" link="#0563C1" vlink="#954F72" style="font-family: Helvetica; font-size: 14px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;">
<div class="WordSection1" style="page: WordSection1;"><br>
<div style="border-style: none none solid; border-bottom-color: windowtext; border-bottom-width: 1pt; padding: 0in 0in 1pt;">
<div style="margin: 0in 0in 0.0001pt; font-size: 11pt; font-family: Calibri, sans-serif; border: none; padding: 0in;">
<o:p> </o:p></div>
</div>
<div style="margin: 0in 0in 0.0001pt; font-size: 11pt; font-family: Calibri, sans-serif;">
<o:p> </o:p></div>
<div style="margin: 0in 0in 0.0001pt; font-size: 11pt; font-family: Calibri, sans-serif;">
The Institute of Medical Engineering and Science is hosting a Distinguished Speaker Series event:<o:p></o:p></div>
<div style="margin: 0in 0in 0.0001pt; font-size: 11pt; font-family: Calibri, sans-serif;">
<o:p> </o:p></div>
<div style="margin: 0in 0in 0.0001pt; font-size: 11pt; font-family: Calibri, sans-serif;">
Dr. Stuart Schreiber from The Broad Institute in Cambridge will present his lecture:<o:p></o:p></div>
<div style="margin: 0in 0in 0.0001pt; font-size: 11pt; font-family: Calibri, sans-serif;">
<o:p> </o:p></div>
<div style="margin: 0in 0in 0.0001pt; font-size: 11pt; font-family: Calibri, sans-serif;">
<b>“Integrating chemistry and biology to discover small-molecule therapeutics”<o:p></o:p></b></div>
<div style="margin: 0in 0in 0.0001pt; font-size: 11pt; font-family: Calibri, sans-serif;">
<b>Wednesday, December 3<sup>rd</sup><span class="Apple-converted-space"> </span>in the Stata Center (32-155)<o:p></o:p></b></div>
<div style="margin: 0in 0in 0.0001pt; font-size: 11pt; font-family: Calibri, sans-serif;">
<b> </b></div>
<div style="margin: 0in 0in 0.0001pt; font-size: 11pt; font-family: Calibri, sans-serif;">
There will be a reception with light refreshments at 4:00 PM, followed by the lecture at 4:30.<o:p></o:p></div>
<div style="margin: 0in 0in 0.0001pt; font-size: 11pt; font-family: Calibri, sans-serif;">
<o:p> </o:p></div>
<div style="margin: 0in 0in 0.0001pt; font-size: 11pt; font-family: Calibri, sans-serif;">
<b>Stuart L. Schreiber, Ph.D.<span class="Apple-converted-space"> </span></b>is the Director of the Center for the Science of Therapeutics and one of four founders of the Broad Institute, where he is a Howard Hughes Medical Institute Investigator. He is also
the Morris Loeb Professor of Chemistry and Chemical Biology at Harvard University, and a member of the National Academy of Sciences.<o:p></o:p></div>
<div style="margin: 0in 0in 0.0001pt; font-size: 11pt; font-family: Calibri, sans-serif;">
<o:p> </o:p></div>
<div style="margin: 0in 0in 0.0001pt; font-size: 11pt; font-family: Calibri, sans-serif;">
Dr. Schreiber’s research integrates chemical biology and human biology to advance the science of therapeutics. He is known for having developed systematic ways to explore biology, especially disease biology, using small molecules and for his role in the development
of the field of chemical biology. He discovered principles that underlie information transfer and storage in cells, specifically discoveries relating to signaling by the phosphatase calcineurin and kinase mTOR (demonstrating for the first time that drugs can
result from the targeting of protein kinases and protein phosphatases), gene regulation by chromatin-modifying histone deacetylases, small-molecule dimerizers that activate cellular processes by enforced proximity, and small-molecule probes of challenging
targets and processes (e.g., transcription factors, oncogenes, protein/protein interactions, transdifferentiation) that relate to human disease. His work has contributed to diversity-oriented synthesis (DOS) and discovery-based small-molecule screening in
an open data-sharing environment. His research has been reported in over 500 publications (H index = 127).<o:p></o:p></div>
<div style="margin: 0in 0in 0.0001pt; font-size: 11pt; font-family: Calibri, sans-serif;">
<o:p> </o:p></div>
<div style="margin: 0in 0in 0.0001pt; font-size: 11pt; font-family: Calibri, sans-serif;">
Schreiber extended chemical biology principles to medicine by participating in the founding of several biotech companies, including Vertex Pharmaceuticals (fosamprenavir/Lexiva; telaprevir/Incivek; ivacaftor/Kalydeco), ARIAD Pharmaceuticals (ponatinib/Iclusig;
AP26113; ridaforolimus; AP1903), Infinity Pharmaceuticals (retaspimycin; duvelisib), Forma Therapeutics and H3 Biomedicine.</div>
</div>
</div>
</blockquote>
</div>
<br>
</body>
</html>